title: Effect of leukotriene C4D4 antagonist on colonic damage induced by intracolonic administration of trinitrobenzene sulfonic acid in rats.
abstract: We examined the effects of eicosanoid antagonists on colonic damage induced by trinitrobenzene sulfonic acid (TNB) in a rat inflammatory bowel model. TNB (30 mg) dissolved in 0.25 ml of 50% ethanol, was given intrarectally. The appropriate doses of ONO-1078 (a leukotriene C4D4 antagonist), ONO-4057 (a leukotriene B4 antagonist), and OKY-046 (a thromboxane A2 synthetase inhibitor) were given to obtain the same blood level, either 4 h before (pre-treatment model) or 24 h after (the post-treatment model) the administration of TNB (n = 8 in all groups). Drugs were given once daily for 6 days through a gastric feeding tube. Autopsy was performed on the 7th day. Colonic damage was assessed in terms of colonic damage scores, and myeloperoxidase (MPO) activity and eicosanoid concentrations in colonic tissues were measured. Compared with the group given TNB alone, the colonic damage score was reduced to 10% in the pre-treatment model with ONO-1078, but the score was not reduced in other groups, MPO activity was not changed in any group. The concentration of leukotriene C4 was reduced with ONO-1078 treatment, in both pre- and post-treatment models. These results demonstrated that a leukotriene C4D4 antagonist reduced colonic inflammation; however, its anti-inflammatory effect was limited in this colitis model.
authors.affiliation: Fourth Department of Internal Medicine, Hyogo College of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Nishikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Hikasa
authors.forename: K
authors.initials: K
authors.lastname: Hori
authors.forename: N
authors.initials: N
authors.lastname: Tanida
authors.forename: T
authors.initials: T
authors.lastname: Shimoyama
mesh_terms: D000818:Animals; D002867:Chromones / Q000494:pharmacology*; D003106:Colon / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D015777:Eicosanoids / Q000378:metabolism; D005260:Female; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D017997:Leukotriene C4 / Q000037:antagonists & inhibitors*; D017998:Leukotriene D4 / Q000037:antagonists & inhibitors*; D008689:Methacrylates / Q000494:pharmacology; D009195:Peroxidase / Q000378:metabolism; D010666:Phenylpropionates / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013189:SRS-A / Q000037:antagonists & inhibitors; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D014302:Trinitrobenzenesulfonic Acid / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D002867:Chromones; D015777:Eicosanoids; D008689:Methacrylates; D010666:Phenylpropionates; D013189:SRS-A; C067523:ONO-LB 457; D017997:Leukotriene C4; D017998:Leukotriene D4; D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase; D013930:Thromboxane-A Synthase; C034364:ozagrel; C047681:pranlukast